Tetraphase Pharmaceuticals Inc Is Climbing Again Today -- Here's Why

What happened

Shares of Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH  ) , a clinical-stage biotech developing antibiotics, continued its impressive climb with another gain of about 15.8%, as of 11:46 a.m. EST on Friday. Following the company's fourth-quarter earnings report on Wednesday, Wall Street analysts continue to raise their price targets for the stock. 

So what

Tetraphase doesn't have any products to sell yet, but investors are more confident that this could change following the company's fourth-quarter and full-year earnings report. Earlier this week, Tetraphase highlighted its progress with its lead antibiotic candidate, intravenous eravacycline for the treatment of complicated intra-abdominal infection (cIAI).

Person running up arrows sloping upward

Image source: Getty Images.

In November, the company released data showing eravacycline was as good, or better, at fighting off infection as carbapenem, a class of antibiotics generally used to treat hospitalized patients with infections caused by bacteria resistant to multiple drugs. The company is running a similar trial pitting its candidate against meropenem, another commonly used antibiotic used to treat cIAI, and expects to announce the results in the fourth quarter this year.

Now what

Another win in the ongoing head-to-head trial against meropenem should be able to support applications to regulatory bodies in the U.S. and the European Union. Hospitals are clamoring for fresh options to treat life-threatening bacterial infections that are increasingly resistant to available antibiotics.

Longtime Tetraphase shareholders can still feel the sting of a market thrashing in 2015 after an oral version of eravacycline flopped in a late-stage trial. Despite somewhat lower demand for the less convenient intravenous version, the antibiotic could go on to generate perhaps $200 million in annual sales. With a market cap of about $260 million, this high-flying biotech stock might have plenty more room to run.

10 stocks we like better than Tetraphase Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Tetraphase Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 6, 2017

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 4007903, ~/Articles/ArticleHandler.aspx, 4/27/2017 2:49:52 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
Change up DOW 20994.0 18.9 0.1%
Change up S&P 500 2390.4 2.9 0.1%
Change up NASD 6046.4 21.2 0.4%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/27/2017 2:33 PM
TTPH $8.07 Down -0.10 -1.22%
Tetraphase Pharmac… CAPS Rating: ****